Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins

Regeneron Pharmaceuticals, Inc. remains a Buy, supported by robust revenue drivers Dupixent and Libtayo, despite recent share price volatility and underperformance versus the S&P. Dupixent’s expanding indications and sustained growth, along with Libtayo’s oncology momentum, underpin forward revenue expectations, even as Eylea faces biosimilar headwinds. Recent margin and ROIC declines are primarily due to accelerated Sanofi repayments and deferred tax asset accumulation, both expected to reverse, improving profitability from Q3 2026. REGN has a strong balance sheet, prudent capital allocation, and a deep pipeline that position REGN for a new growth phase, with operating margins and ROIC likely bottoming in 2026.

Regeneron Pharmaceuticals, Inc. ( REGN ), based in Tarrytown, NJ, is a leading biotechnology company with a fantastic track-record of rewarding shareholders over its lifetime. However, shares have fallen from their peak of ~$1200 in August 2024 to around $660 today.